<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>HYPOTHESIS: Cyclooxygenase 2 (COX-2), vascular endothelial growth factor (VEGF), and epidermal growth factor receptor (EGFR) are useful biological determinants in targeted therapy for esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>DESIGN: Prospective analysis </plain></SENT>
<SENT sid="2" pm="."><plain>SETTING: University tertiary referral center </plain></SENT>
<SENT sid="3" pm="."><plain>PATIENTS: Sixteen patients with squamous mucosa and <z:mpath ids='MPATH_458'>normal</z:mpath> results of a pH study without mucosal injury (control group), 15 with <z:hpo ids='HP_0100580'>Barrett esophagus</z:hpo> (<z:mpath ids='MPATH_160'>metaplasia</z:mpath> group), and 44 with <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> (<z:mp ids='MP_0002038'>carcinoma</z:mp> group) </plain></SENT>
<SENT sid="4" pm="."><plain>INTERVENTIONS: Biopsy specimens were obtained 3 cm above the gastroesophageal junction </plain></SENT>
<SENT sid="5" pm="."><plain>Dysplastic tissue was additionally isolated from 9 of the patients in the <z:mp ids='MP_0002038'>carcinoma</z:mp> group </plain></SENT>
<SENT sid="6" pm="."><plain>After laser-capture microdissection, quantitative real-time polymerase chain reaction was used to measure gene expression across the spectrum of the <z:mpath ids='MPATH_160'>metaplasia</z:mpath>-<z:mpath ids='MPATH_589'>dysplasia</z:mpath>-<z:mp ids='MP_0002038'>carcinoma</z:mp> sequence </plain></SENT>
<SENT sid="7" pm="."><plain>MAIN OUTCOME MEASURES: Expression of COX-2, VEGF, and EGFR in each patient group </plain></SENT>
<SENT sid="8" pm="."><plain>RESULTS: Expression of both COX-2 and VEGF was significantly up-regulated in patients with <z:mpath ids='MPATH_160'>metaplasia</z:mpath>, <z:mpath ids='MPATH_589'>dysplasia</z:mpath>, and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> compared with controls (P&lt;.01) </plain></SENT>
<SENT sid="9" pm="."><plain>Expression levels of both were significantly higher in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> than in the <z:mpath ids='MPATH_160'>metaplasia</z:mpath> group (P&lt;.05) and increased sequentially from <z:mpath ids='MPATH_160'>metaplasia</z:mpath> to <z:mpath ids='MPATH_589'>dysplasia</z:mpath> to <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>Expression of VEGF was significantly higher in the dysplastic tissue than in nondysplastic <z:e sem="disease" ids="C1258085" disease_type="Disease or Syndrome" abbrv="">Barrett epithelium</z:e> (P&lt;.05) </plain></SENT>
<SENT sid="11" pm="."><plain>No change in expression levels of EGFR was seen in the histologic progression to esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSION: Gene expression data suggest that pharmacologic inhibition of COX-2 and VEGF may be useful adjuncts in targeted therapy for esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
</text></document>